GlassScriptPhysician profile
Valeri L Roth
NPI 1457334997
$7,340.70
in general payments reported to CMS, 2019-2025
28 companies · $2,339 in 2025
The $2,339 reported for 2025 was more than what 91% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $525 · 2020: $204 · 2021: $412 · 2022: $1,572 · 2023: $1,377 · 2024: $911 · 2025: $2,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,627.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,954.79 | 2021-2025 | Nucala, Benlysta |
| Inspire Medical Systems, INC. | $1,196.77 | 2022-2025 | Inspire |
| Revance Therapeutics, INC. | $887.39 | 2025 | Daxxify |
| Regeneron Healthcare Solutions, INC. | $691.78 | 2020-2025 | Dupixent |
| Genzyme Corporation | $398.93 | 2020-2024 | |
| Acclarent, INC | $377.17 | 2019-2023 | Acclarent Aera |
| Optinose US, INC. | $345.57 | 2019-2025 | |
| Kaleo, INC. | $290.13 | 2019-2024 | Auvi-Q |
| Aerin Medical INC. | $233.59 | 2019-2025 | |
| Boston Scientific Corporation | $173.61 | 2022-2023 | Watchman Access System, Rezum Generator |
| Novo Nordisk INC | $141.24 | 2023 | Wegovy |
| Verona Pharma, INC. | $103.40 | 2025 | Ohtuvayre |
| Allergan, INC. | $86.78 | 2019-2022 | |
| Alk-Abello, INC | $80.97 | 2020-2025 | Timothy, Standardized, Pre-Pen, Standardized Mite D. Farinae |
| Smith+Nephew, INC. | $60.58 | 2025 | Stravix, Grafix Pl |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $59.51 | 2023 | Coolseal Generator |
| Genentech USA, INC. | $46.06 | 2019-2025 | Xolair |
| Merz North America, INC. | $29.19 | 2024 | |
| Zoll Respicardia, INC. | $25.43 | 2025 | Remede System |
| Amgen INC. | $21.60 | 2025 | Tezspire |
| Galderma Laboratories, L.P. | $20.84 | 2025 | |
| Stryker Corporation | $19.07 | 2022 | |
| Greer Laboratories, INC. | $18.07 | 2019 | |
| Kerecis Limited | $16.61 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Phadia US INC. | $16.23 | 2024 | Immunocap |
| Misonix INC | $15.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.67 | 2025 | Tezspire |
| Abbvie INC. | $13.75 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valeri Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.